| Description | This product is a human-mouse chimeric neutralizing monoclonal antibody, which effectively neutralize anthrax lethal toxin (EC50 = 1.68 nM) as proved by in vitro experiment and animal experiment. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Bacillus anthracis |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
| Application | ELISA; Neut; FuncS |
| Application Notes | HcLF8 antibody can be protected cell effectively, the necrocytosis of avoiding anthrax toxin to cause, median effective dose EC50 = 1.68 nM. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | Anthrax LF |
| Alternative Name | Anthrax lethal factor; LF |
| Research Area | Infectious Disease |
